Harnessing preclinical mouse models to inform human clinical cancer trials
Open Access
- 23 March 2006
- journal article
- review article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 116 (4) , 847-852
- https://doi.org/10.1172/jci28271
Abstract
The urgent need for better cancer treatments has stimulated interest in employing small-animal models to evaluate potential drug therapies. Robust mouse models of many human cancers have been generated using sophisticated technologies for engineering germ-line mutations. As we enter into an age of targeted therapeutics, these strains provide novel platforms for validating new anticancer drugs, assessing therapeutic index, identifying surrogate markers of tumor progression, and defining epigenetic and environmental influences on tumorigenesis.Keywords
This publication has 95 references indexed in Scilit:
- Molecular Determinants of the Response of Glioblastomas to EGFR Kinase InhibitorsNew England Journal of Medicine, 2005
- BRAF mutation predicts sensitivity to MEK inhibitionNature, 2005
- Evasion of the p53 tumour surveillance network by tumour-derived MYC mutantsNature, 2005
- Neurogenic tumors in rats induced by ethylnitrosoureaExperimental and Toxicologic Pathology, 2005
- Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorderBlood, 2004
- Combination of epidermal growth factor receptor targeted therapy with radiation therapy for malignant gliomasFrontiers in Bioscience-Landmark, 2003
- Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouseGenes & Development, 2002
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001
- Tumor-associated Apc mutations in Mlh1−/−Apc1638N mice reveal a mutational signature of Mlh1 deficiencyOncogene, 2000
- Development of a flexible and specific gene delivery system for production of murine tumor modelsOncogene, 1999